Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glucose monitor helps type 2 diabetes patients on insulin

NCT ID NCT06268808

Disease control Sponsor: Abbott Diabetes Care Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether starting the FreeStyle Libre 2 continuous glucose monitor helps adults with type 2 diabetes who use basal insulin. Over three months, researchers measured changes in HbA1c and time spent in healthy blood sugar range. The study included 90 adults aged 18 to 75 with type 2 diabetes for at least one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jul 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 to ≤ 75 years. * Type 2 diabetes diagnosis ≥1 year prior to enrolment. * Type 2 diabetes treated with a basal insulin injection regimen with or without other antihyperglycaemic therapy at enrolment. * Current glucose lowering treatment regimen has been established for at least 3 months prior to enrolment. * Screening HbA1c ≥59 mmol/mol to ≤108 mmol/mol (≥7.5% and ≤12.0%, inclusive), within the last 60 days. Exclusion Criteria: * Participant is currently prescribed prandial or pre-mixed (biphasic) insulin at enrolment. * Currently participating in another study that could affect glucose measurements or glucose management. * Currently receiving dialysis treatment or receives dialysis during the study. * A female participant who is pregnant. * A breastfeeding female participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes treated with insulin are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes treated with insulin

Contacts and locations

Locations

  • ASL Toscana Nord Ovest

    Livorno, Italy

  • ASL Toscana Nordovest

    Carrara, Italy

  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

    Bari, Italy

  • Azienda Ospedaliero- Universitaria "Renato Dulbecco" di Catanzaro

    Catanzaro, Italy

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, Italy

  • La Sapienza Università di Roma, AOU Policlinico Umberto I

    Rome, Italy

  • Università degli Studi di Catania, Ospedale Garibaldi-Nesima, U.O. Endocrinologia

    Catania, Italy

  • Università degli Studi di Catania, Ospedale Garibaldi-Nesima, U.O.C. Medicina Interna

    Catania, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.